FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility
Executive Summary
FDA is planning a public meeting to discuss the new priority review voucher system to begin implementing the new program
You may also be interested in...
FDA Mulls “Fast Track” Approach For Priority Review Voucher Eligibility
FDA should consider setting up a process to pre-determine whether a product being developed for a neglected tropical disease will qualify for a priority review voucher, BIO Ventures for Global Health VP-Strategy & Operations Wendy Taylor said Dec. 12 at a public hearing convened by the agency
FDA Mulls “Fast Track” Approach For Priority Review Voucher Eligibility
FDA should consider setting up a process to pre-determine whether a product being developed for a neglected tropical disease will qualify for a priority review voucher, BIO Ventures for Global Health VP-Strategy & Operations Wendy Taylor said Dec. 12 at a public hearing convened by the agency
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies